Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, disclosed its decision to invest ¥700 million (US$6.2 million) in Meltin MMI, of Tokyo. At the same time, the two companies signed a joint research and development agreement. Meltin aims to enhance the functionality of cyborg technologies and the combination of bio-signal processing and robotics.  than pharmaceuticals as "frontier areas," with the aim of exploring new business opportunities.